section name header

Pronunciation

IN-su-lin

Classifications

Therapeutic Classification: antidiabetics, hormones

Pharmacologic Classification: pancreatics

Indications

BEERS REMS, High Alert


Concentrated regular insulin U-500

Unlabeled Use:

Action

  • Lowers blood glucose by:
    • stimulating glucose uptake in skeletal muscle and fat,
    • inhibiting hepatic glucose production.
  • Other actions of insulin:
    • inhibition of lipolysis and proteolysis,
    • enhanced protein synthesis.
Therapeutic effects:
  • Control of hyperglycemia in diabetic patients.

Pharmacokinetics

Absorption: Rapidly absorbed from SUBQ administration sites. U-100 regular insulin is absorbed slightly more quickly than U-500. IV administration results in complete bioavailability.

Distribution: Identical to endogenous insulin.

Metabolism/Excretion: Metabolized by liver, spleen, kidney, and muscle.

Half-Life: 30–60 min.

Time/Action Profile

(hypoglycemic effect)

ROUTEONSETPEAKDURATION
IV10–30 min15–30 min30–60 min
SUBQ30–60 min2–4 hr5–7 hr





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Endo: HYPOGLYCEMIA

F and E: hypokalemia

Local: cutaneous amyloidosis, erythema, lipodystrophy, pruritus, swelling

Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS)

Interactions

Drug-drug:

Drug-Natural Products:

Route/Dosage

Ketoacidosis—Regular (100 units/mL) Insulin Only

Maintenance Therapy

Treatment of Hyperkalemia

Availability

Assessment

Lab Test Considerations:

Toxicity and Overdose:

Implementation

IV Administration:

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

HumuLIN R, HumuLIN R U-500 (Concentrated), HumuLIN R U-500 KwikPen (Concentrated), Myxredlin, NovoLIN R, NovoLIN R FlexPen

Canadian Brand Names

Entuzity Kwikpen